GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViroGates A/S (OCSE:VIRO) » Definitions » Return-on-Tangible-Equity

ViroGates A/S (OCSE:VIRO) Return-on-Tangible-Equity : -94.57% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is ViroGates A/S Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. ViroGates A/S's annualized net income for the quarter that ended in Mar. 2024 was kr-14.38 Mil. ViroGates A/S's average shareholder tangible equity for the quarter that ended in Mar. 2024 was kr15.21 Mil. Therefore, ViroGates A/S's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -94.57%.

The historical rank and industry rank for ViroGates A/S's Return-on-Tangible-Equity or its related term are showing as below:

OCSE:VIRO' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -105.7   Med: -59.73   Max: -36.42
Current: -105.7

During the past 8 years, ViroGates A/S's highest Return-on-Tangible-Equity was -36.42%. The lowest was -105.70%. And the median was -59.73%.

OCSE:VIRO's Return-on-Tangible-Equity is ranked worse than
85.41% of 761 companies
in the Medical Devices & Instruments industry
Industry Median: 1.39 vs OCSE:VIRO: -105.70

ViroGates A/S Return-on-Tangible-Equity Historical Data

The historical data trend for ViroGates A/S's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViroGates A/S Return-on-Tangible-Equity Chart

ViroGates A/S Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial -36.42 -50.96 -74.00 -59.33 -73.10

ViroGates A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -80.51 -131.47 -101.68 -109.06 -94.57

Competitive Comparison of ViroGates A/S's Return-on-Tangible-Equity

For the Medical Devices subindustry, ViroGates A/S's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViroGates A/S's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViroGates A/S's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where ViroGates A/S's Return-on-Tangible-Equity falls into.



ViroGates A/S Return-on-Tangible-Equity Calculation

ViroGates A/S's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-12.096/( (16.088+17.008 )/ 2 )
=-12.096/16.548
=-73.10 %

ViroGates A/S's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-14.384/( (17.008+13.412)/ 2 )
=-14.384/15.21
=-94.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


ViroGates A/S  (OCSE:VIRO) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


ViroGates A/S Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of ViroGates A/S's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


ViroGates A/S (OCSE:VIRO) Business Description

Traded in Other Exchanges
N/A
Address
Banevaenget 13, Birkerod, DNK, DK-3460
ViroGates A/S is a life science company that develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular, to make a clinical decision on hospitalization or discharge of emergency patients. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, and cancer. It has developed a product line called suPARnostic to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision-making.

ViroGates A/S (OCSE:VIRO) Headlines

No Headlines